Legal & General Group
IONS icon

Legal & General Group’s Ionis Pharmaceuticals IONS Stock Holding History

Legal & General Group’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.1M Sell
294,679
-30,469
-9% -$2.4M 0.01% 783
2025
Q4 		$25.7M Buy
325,148
+5,583
+2% +$420K 0.01% 767
2025
Q3 		$20.9M Sell
319,565
-84,801
-21% -$4.14M ﹤0.01% 844
2025
Q2 		$16M Buy
404,366
+65,904
+19% +$2.16M ﹤0.01% 948
2025
Q1 		$10.2M Buy
338,462
+170,382
+101% +$5.58M ﹤0.01% 1127
2024
Q4 		$5.88M Buy
168,080
+10,793
+7% +$403K ﹤0.01% 1499
2024
Q3 		$6.3M Buy
157,287
+9,643
+7% +$449K ﹤0.01% 1465
2024
Q2 		$7.04M Sell
147,644
-1,844
-1% -$75.6K ﹤0.01% 1338
2024
Q1 		$6.48M Sell
149,488
-5,860
-4% -$279K ﹤0.01% 1384
2023
Q4 		$7.86M Sell
155,348
-9,687
-6% -$464K ﹤0.01% 1272
2023
Q3 		$7.49M Buy
165,035
+31,692
+24% +$1.31M ﹤0.01% 1215
2023
Q2 		$5.47M Sell
133,343
-7,375
-5% -$283K ﹤0.01% 1409
2023
Q1 		$5.03M Buy
140,718
+13,630
+11% +$512K ﹤0.01% 1412
2022
Q4 		$4.8M Sell
127,088
-1,365
-1% -$57.4K ﹤0.01% 1424
2022
Q3 		$5.68M Sell
128,453
-35,501
-22% -$1.5M ﹤0.01% 1307
2022
Q2 		$6.07M Buy
163,954
+1,636
+1% +$61.7K ﹤0.01% 1323
2022
Q1 		$6.01M Buy
162,318
+3,974
+3% +$130K ﹤0.01% 1419
2021
Q4 		$4.82M Sell
158,344
-9,077
-5% -$286K ﹤0.01% 1584
2021
Q3 		$5.62M Buy
167,421
+41,538
+33% +$1.57M ﹤0.01% 1484
2021
Q2 		$5.02M Sell
125,883
-294,494
-70% -$11.5M ﹤0.01% 1530
2021
Q1 		$18.9M Sell
420,377
-45,321
-10% -$2.53M 0.01% 903
2020
Q4 		$26.3M Buy
465,698
+31,193
+7% +$1.55M 0.01% 769
2020
Q3 		$20.6M Sell
434,505
-18,438
-4% -$1.02M 0.01% 781
2020
Q2 		$26.7M Buy
452,943
+17,905
+4% +$996K 0.01% 720
2020
Q1 		$20.6M Buy
435,038
+28,404
+7% +$1.58M 0.01% 723
2019
Q4 		$24.6M Buy
406,634
+16,386
+4% +$976K 0.01% 758
2019
Q3 		$23.4M Buy
390,248
+34,465
+10% +$2.25M 0.01% 748
2019
Q2 		$22.9M Buy
355,783
+283,306
+391% +$20M 0.01% 753
2019
Q1 		$5.88M Buy
72,477
+1,901
+3% +$123K ﹤0.01% 1087
2018
Q4 		$3.82M Buy
70,576
+8,653
+14% +$441K ﹤0.01% 1220
2018
Q3 		$3.19M Buy
61,923
+3,042
+5% +$143K ﹤0.01% 1467
2018
Q2 		$2.45M Sell
58,881
-9,571
-14% -$424K ﹤0.01% 1564
2018
Q1 		$3.02M Buy
68,452
+1,925
+3% +$97.8K ﹤0.01% 1387
2017
Q4 		$3.35M Buy
66,527
+13,690
+26% +$751K ﹤0.01% 1329
2017
Q3 		$2.68M Buy
52,837
+8,357
+19% +$438K ﹤0.01% 1418
2017
Q2 		$2.26M Buy
44,480
+3,944
+10% +$184K ﹤0.01% 1460
2017
Q1 		$1.63M Buy
40,536
+27,512
+211% +$1.24M ﹤0.01% 1598
2016
Q4 		$623K Buy
13,024
+1,542
+13% +$61K ﹤0.01% 1918
2016
Q3 		$420K Sell
11,482
-53,478
-82% -$1.67M ﹤0.01% 1786
2016
Q2 		$1.51M Buy
64,960
+6,779
+12% +$219K ﹤0.01% 1049
2016
Q1 		$2.36M Buy
58,181
+15,308
+36% +$622K ﹤0.01% 873
2015
Q4 		$2.65M Buy
42,873
+3,325
+8% +$179K ﹤0.01% 871
2015
Q3 		$1.6M Buy
39,548
+3,931
+11% +$203K ﹤0.01% 984
2015
Q2 		$2.05M Sell
35,617
-17,740
-33% -$1.13M ﹤0.01% 942
2015
Q1 		$3.43M Buy
53,357
+36,050
+208% +$2.45M ﹤0.01% 793
2014
Q4 		$1.09M Sell
17,307
-457
-3% -$22.6K ﹤0.01% 1065
2014
Q3 		$698K Buy
+17,764
New +$630K ﹤0.01% 1127

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Legal & General Group's IONS Position: Q1 2026 in Review

Legal & General Group reduced its Ionis Pharmaceuticals (IONS) stake by 9.4% in Q1 2026, selling an estimated $2.4M and leaving 294,679 shares worth $22.1M. The position accounts for 0.01% of the portfolio, ranked #783.

Legal & General Group first reported a position in IONS in Q3 2014 and has held it in 47 quarters since. The position peaked at $26.7M in Q2 2020. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Legal & General Group held 294,679 shares of Ionis Pharmaceuticals worth $22.1M as of Q1 2026.
  • Legal & General Group sold 30,469 Ionis Pharmaceuticals shares in Q1 2026, an estimated $2.4M.
  • Ionis Pharmaceuticals made up 0.01% of Legal & General Group's portfolio in Q1 2026, its #783 holding.
  • Legal & General Group first reported a position in Ionis Pharmaceuticals in Q3 2014 and has held it in 47 quarters since.
  • Legal & General Group's Ionis Pharmaceuticals position peaked at $26.7M in Q2 2020.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.